Photosensitising drugs - their potential in oncology

Author： Brown J.E. Brown S.B. Vernon D.I.

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.8, Iss.12, 1999-12, pp. : 1967-1979

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Discontinued drugs in 2012: oncology drugs

By Williams Robert

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 12, 2013-12 ,pp. : 1627-1644

Informa Healthcare

Access to resources Recommend Favorite

Discontinued drugs in 2007: oncology drugs

By Williams Robert

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 12, 2008-12 ,pp. : 1791-1816

Informa Healthcare

Access to resources Recommend Favorite

Discontinued drugs in 2006: oncology drugs

By Williams Robert

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 269-283

Informa Healthcare

Access to resources Recommend Favorite

The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs

Current Pharmaceutical Design, Vol. 21, Iss. 25, 2015-08 ,pp. : 3644-3653

Bentham Science Publishers

Access to resources Recommend Favorite

The notorious “drug lag for oncology drugs in Japan

By Yonemori Kan

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 706-712

Springer Publishing Company

Access to resources Recommend Favorite